Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Endocrinol Metab. 2003 Apr-May;16(4):529-36.

Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children.

Author information

1
Pediatrics Department, Unitat Integrada Hospital Sant Joan de Déu-Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.

Abstract

BACKGROUND:

Long-term corticoids used as a treatment for rheumatic diseases are the most frequent cause of osteoporosis in the pediatric population. Bisphosphonates have been proved to be useful in treating osteoporosis.

OBJECTIVE:

To investigate the efficacy of pamidronate in corticoid-induced osteoporosis in children.

PATIENTS AND METHODS:

Ten children affected with rheumatic diseases and osteoporosis underwent biannual cycles of intravenous pamidronate (4 to 12 cycles). Complete clinical, radiological, biochemical and densitometric follow-up was performed at every treatment cycle.

RESULTS:

Good clinical and radiological evolution was observed in most of our patients; no new vertebral fractures were reported. Good densitometric evolution has been linked to the onset of puberty (rise in IGF-I levels) and low values for inflammatory activity markers (ESR and CRP). Self-limited hyperthermia and mild abdominal pain were observed during pamidronate infusion, but no other side effects were reported.

CONCLUSIONS:

Pamidronate is a safe and useful treatment for corticoid-induced osteoporosis in the pediatric population.

PMID:
12793604
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center